21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients

Sadako Akashi-Tanaka; Chikako Shimizu; Masashi Ando; Tatsuhiro Shibata; Noriyuki Katsumata; Tsutomu Kouno; Kotoe Terada; Tadahiko Shien; Miwa Yoshida; Takashi Hojo; Takayuki Kinoshita; Yasuhiro Fujiwara; Kenichi Yoshimura

doi:10.1016/j.breast.2009.03.005

21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients

Sadako Akashi-Tanaka, Chikako Shimizu, Masashi Ando, Tatsuhiro Shibata, Noriyuki Katsumata, Tsutomu Kouno, Kotoe Terada, Tadahiko Shien, Miwa Yoshida, Takashi Hojo, Takayuki Kinoshita, Yasuhiro Fujiwara, Kenichi Yoshimura

Research output: Contribution to journal › Article › peer-review

43 Citations (Scopus)

Abstract

This study examined postmenopausal estrogen receptor-positive breast cancer patients who received prospective neoadjuvant endocrine therapy (NAET) with tamoxifen or anastrozole to determine if the 21-gene recurrence score (RS) predicts NAET responses. RS scores were determined from pretreatment core biopsy specimens. Although half of the specimens yielded insufficient RNA, the remaining samples were highly representative. Patients with a low RS tended to respond better than those with an intermediate or high RS (n = 43). Response rates by RS were similar between the tamoxifen and anastrozole groups. Patients with a low RS tended to have better relapse-free survival (RFS) than those with an intermediate or high RS (5y-RFS; 100% vs. 84% and 73%, respectively). These results suggest that RS predicts responses to NAET with tamoxifen or anastrozole. Because this pilot study examined a small sample size, these results should be validated in larger studies.

Original language	English
Pages (from-to)	171-174
Number of pages	4
Journal	Breast
Volume	18
Issue number	3
DOIs	https://doi.org/10.1016/j.breast.2009.03.005
Publication status	Published - Jun 2009
Externally published	Yes

Keywords

Breast cancer
Multigene assay
Neoadjuvant endocrine therapy
Predictive factor
Recurrence score

ASJC Scopus subject areas

Surgery

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.breast.2009.03.005

Cite this

Akashi-Tanaka, S., Shimizu, C., Ando, M., Shibata, T., Katsumata, N., Kouno, T., Terada, K., Shien, T., Yoshida, M., Hojo, T., Kinoshita, T., Fujiwara, Y., & Yoshimura, K. (2009). 21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients. Breast, 18(3), 171-174. https://doi.org/10.1016/j.breast.2009.03.005

Akashi-Tanaka, S, Shimizu, C, Ando, M, Shibata, T, Katsumata, N, Kouno, T, Terada, K, Shien, T, Yoshida, M, Hojo, T, Kinoshita, T, Fujiwara, Y & Yoshimura, K 2009, '21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients', Breast, vol. 18, no. 3, pp. 171-174. https://doi.org/10.1016/j.breast.2009.03.005

@article{b9037be3a1334afda6ff73723512f32f,

title = "21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients",

abstract = "This study examined postmenopausal estrogen receptor-positive breast cancer patients who received prospective neoadjuvant endocrine therapy (NAET) with tamoxifen or anastrozole to determine if the 21-gene recurrence score (RS) predicts NAET responses. RS scores were determined from pretreatment core biopsy specimens. Although half of the specimens yielded insufficient RNA, the remaining samples were highly representative. Patients with a low RS tended to respond better than those with an intermediate or high RS (n = 43). Response rates by RS were similar between the tamoxifen and anastrozole groups. Patients with a low RS tended to have better relapse-free survival (RFS) than those with an intermediate or high RS (5y-RFS; 100% vs. 84% and 73%, respectively). These results suggest that RS predicts responses to NAET with tamoxifen or anastrozole. Because this pilot study examined a small sample size, these results should be validated in larger studies.",

keywords = "Breast cancer, Multigene assay, Neoadjuvant endocrine therapy, Predictive factor, Recurrence score",

author = "Sadako Akashi-Tanaka and Chikako Shimizu and Masashi Ando and Tatsuhiro Shibata and Noriyuki Katsumata and Tsutomu Kouno and Kotoe Terada and Tadahiko Shien and Miwa Yoshida and Takashi Hojo and Takayuki Kinoshita and Yasuhiro Fujiwara and Kenichi Yoshimura",

note = "Funding Information: This study was supported in part by a Grant-in Aid for research of cancer treatment (17-7) from the Ministry of Health, labor and welfare of Japan and Genomic Health. Genomic Health paid the costs of shipping the paraffin-embedded tissue sections and performing all RT-PCR assays.",

year = "2009",

month = jun,

doi = "10.1016/j.breast.2009.03.005",

language = "English",

volume = "18",

pages = "171--174",

journal = "Breast",

issn = "0960-9776",

publisher = "Churchill Livingstone",

number = "3",

}

TY - JOUR

T1 - 21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients

AU - Akashi-Tanaka, Sadako

AU - Shimizu, Chikako

AU - Ando, Masashi

AU - Shibata, Tatsuhiro

AU - Katsumata, Noriyuki

AU - Kouno, Tsutomu

AU - Terada, Kotoe

AU - Shien, Tadahiko

AU - Yoshida, Miwa

AU - Hojo, Takashi

AU - Kinoshita, Takayuki

AU - Fujiwara, Yasuhiro

AU - Yoshimura, Kenichi

N1 - Funding Information: This study was supported in part by a Grant-in Aid for research of cancer treatment (17-7) from the Ministry of Health, labor and welfare of Japan and Genomic Health. Genomic Health paid the costs of shipping the paraffin-embedded tissue sections and performing all RT-PCR assays.

PY - 2009/6

Y1 - 2009/6

N2 - This study examined postmenopausal estrogen receptor-positive breast cancer patients who received prospective neoadjuvant endocrine therapy (NAET) with tamoxifen or anastrozole to determine if the 21-gene recurrence score (RS) predicts NAET responses. RS scores were determined from pretreatment core biopsy specimens. Although half of the specimens yielded insufficient RNA, the remaining samples were highly representative. Patients with a low RS tended to respond better than those with an intermediate or high RS (n = 43). Response rates by RS were similar between the tamoxifen and anastrozole groups. Patients with a low RS tended to have better relapse-free survival (RFS) than those with an intermediate or high RS (5y-RFS; 100% vs. 84% and 73%, respectively). These results suggest that RS predicts responses to NAET with tamoxifen or anastrozole. Because this pilot study examined a small sample size, these results should be validated in larger studies.

AB - This study examined postmenopausal estrogen receptor-positive breast cancer patients who received prospective neoadjuvant endocrine therapy (NAET) with tamoxifen or anastrozole to determine if the 21-gene recurrence score (RS) predicts NAET responses. RS scores were determined from pretreatment core biopsy specimens. Although half of the specimens yielded insufficient RNA, the remaining samples were highly representative. Patients with a low RS tended to respond better than those with an intermediate or high RS (n = 43). Response rates by RS were similar between the tamoxifen and anastrozole groups. Patients with a low RS tended to have better relapse-free survival (RFS) than those with an intermediate or high RS (5y-RFS; 100% vs. 84% and 73%, respectively). These results suggest that RS predicts responses to NAET with tamoxifen or anastrozole. Because this pilot study examined a small sample size, these results should be validated in larger studies.

KW - Breast cancer

KW - Multigene assay

KW - Neoadjuvant endocrine therapy

KW - Predictive factor

KW - Recurrence score

UR - http://www.scopus.com/inward/record.url?scp=67349183387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349183387&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2009.03.005

DO - 10.1016/j.breast.2009.03.005

M3 - Article

C2 - 19410462

AN - SCOPUS:67349183387

SN - 0960-9776

VL - 18

SP - 171

EP - 174

JO - Breast

JF - Breast

IS - 3

ER -

21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this